Chapter 3 Market Overview
3.1 Type 2 Diabetes Overview
3.1.1 What is Type 2 Diabetes?
3.1.2 Prevalence and Epidemiology of Type 2 Diabetes
3.1.3 Diagnosing Type 2 Diabetes
3.1.4 Treatment for Type 2 Diabetes
3.2 Market Drivers
3.2.1 Rising Prevalence of Diabetes
3.2.2 Next Generation of Type 2 Diabetes Treatment
3.2.3 High Unmet Need
3.2.4 Premium Pricing
3.2.5 Collaborations and Licensing Agreements
3.3 Market Challenge
3.3.1 Loss of Exclusivity, Genericization and Pricing Pressure
3.3.2 Evolving Regulatory Scenario
3.4 Impact of Covid-19
Chapter 4 Emerging Trends and Opportunities
4.1 Patient Outcomes Beyond Glucose Control
4.2 Diabetes Technology With Digital Health
4.3 Growing Trend Toward Oral Antidiabetics
4.4 Growing Focus on Accessibility and Affordability of Medicine
Chapter 5 Market Breakdown by Route of Administration and Therapy Type
5.1 Type 2 Diabetes Treatment Market by Route of Administration
5.1.1 Market Size and Forecast
5.2 Injectable Therapies Market by Type
5.2.1 Insulin Therapy
5.2.2 Glucagon-Like Peptide 1 Therapy
5.2.3 Market Size and Forecast
5.3 Oral Medications Market by Drug Class
5.3.1 Dipeptidyl Peptidase-4 Inhibitors
5.3.2 Sodium-Glucose Cotransporter-2 Inhibitors
5.3.3 Glucagon-Like Peptide 1 Receptor Agonists
5.3.4 Other Oral Antidiabetic Medications
5.3.5 Market Size and Forecast
5.4 Type 2 Diabetes Treatment Market by Therapy Type
5.4.1 Market Size and Forecast
5.5 Insulin Therapy Market by Insulin Type
5.5.1 Market Size and Forecast
5.6 Non-Insulin Therapies Market by Drug Type
5.6.1 Market Size and Forecast
Chapter 6 Market Breakdown by Region
6.1 Type 2 Diabetes Treatment Market Size by Region
6.2 North America
6.3 Europe
6.4 Asia-Pacific
6.5 Rest of the World
Chapter 7 Competitive Landscape
7.1 Global Market Shares of Leading Companies
7.2 Recent Key Developments
7.3 Blockbuster Diabetes Drug and Therapy Revenue
7.4 Facing the Patent Cliff
Chapter 8 Company Profiles
- Astrazeneca plc
- Biocon
- Boehringer Ingelheim International GmbH
- Eli Lilly and Co.
- Janssen Pharmaceuticals Inc. (Johnson & Johnson)
- Merck & Co. Inc.
- Novartis AG
- Novo Nordisk A/S
- Sanofi
Chapter 9 Project Scope and Methodology
9.1 Scope of Report
9.2 Methodology
9.3 Analyst's Credentials
9.4 Custom Research
9.5 Related Research Reports
List of Tables
Summary Table: Global Market for Type 2 Diabetes Treatment, by Region, Through 2027
Table 1: Global Diabetes Estimates and Projections, 2019-2045
Table 2: Global Prevalence of Diabetes, by Type, Through 2040
Table 3: Age-Adjusted Comparative Prevalence of Diabetes, by Region, 2010-2040
Table 4: First-Time Generic Drug Approvals for Type 2 Diabetes, October 2022-2021
Table 5: Global Market for Type 2 Diabetes Treatment, by Route of Administration, Through 2027
Table 6: Global Market for Injectable Therapies for Type 2 Diabetes, by Type, Through 2027
Table 7: Medications in the DPP-4 Inhibitor Family
Table 8: Medications in the SGLT2 Inhibitor Family
Table 9: Oral GLP-1 Receptor Agonists
Table 10: Global Market for Oral Medications for Type 2 Diabetes, by Drug Class, Through 2027
Table 11: Global Market for Type 2 Diabetes Treatment, by Therapy Type, Through 2027
Table 12: Insulin Types and Their Features
Table 13: Leading Insulin Products and Their Types
Table 14: Global Market for Insulin for Type 2 Diabetes Treatment, by Insulin Type, Through 2027
Table 15: Global Market for Non-Insulin Therapies for Type 2 Diabetes, by Drug Type, Through 2027
Table 16: Global Market for Type 2 Diabetes Treatment, by Region, Through 2027
Table 17: North American Market for Type 2 Diabetes Treatment, by Route of Administration, Through 2027
Table 18: North American Market for Injectable Therapies for Type 2 Diabetes, by Therapy Type, Through 2027
Table 19: North American Market for Oral Medications Type 2 Diabetes, by Drug Class, Through 2027
Table 20: North American Market for Type 2 Diabetes Treatment, by Country, Through 2027
Table 21: European Market for Type 2 Diabetes Treatment, by Route of Administration, Through 2027
Table 22: European Market for Injectable Therapies for Type 2 Diabetes, by Therapy Type, Through 2027
Table 23: European Market for Oral Medications Type 2 Diabetes, by Drug Class, Through 2027
Table 24: European Market for Type 2 Diabetes Treatment, by Country, Through 2027
Table 25: Asia-Pacific Market for Type 2 Diabetes Treatment, by Route of Administration, Through 2027
Table 26: Asia-Pacific Market for Injectable Therapies for Type 2 Diabetes, by Therapy Type, Through 2027
Table 27: Asia-Pacific Market for Oral Medications Type 2 Diabetes, by Drug Class, Through 2027
Table 28: Asia-Pacific Market for Type 2 Diabetes Treatment, by Country, Through 2027
Table 29: RoW Market for Type 2 Diabetes Treatment, by Route of Administration, Through 2027
Table 30: RoW Market for Injectable Therapies for Type 2 Diabetes, by Therapy Type, Through 2027
Table 31: RoW Oral Medications Market for Type 2 Diabetes, by Drug Class, Through 2027
Table 32: RoW Type 2 Diabetes Treatment, by Sub-Region, Through 2027
Table 33: Global Market Shares of Type 2 Diabetes Therapies Manufacturers, 2021
Table 34: Global Type 2 Diabetes Treatment Market, Selected Recent Key Developments, September 2019-August 2022
Table 35: Global Sales of the Blockbuster Diabetes Drugs and Therapies, 2021
Table 36: Blockbuster Diabetes Therapies, by Therapy Type, 2021
Table 37: Global Evolution of the Top-Selling Diabetes Drug and Therapy Brands, 2016-2021
Table 38: U.S. Patent Expiry Dates for the Blockbuster Diabetes Drugs, 2021
Table 39: Astrazeneca: Product Portfolio for Type 2 Diabetes Treatment
Table 40: Astrazeneca: Selected Key Developments, 2020-October 2022
Table 41: Biocon: Product Portfolio for Type 2 Diabetes Treatment
Table 42: Biocon: Selected Key Developments, 2020-October 2022
Table 43: Boehringer Ingelheim: Products Portfolio for Type 2 Diabetes Treatment
Table 44: Boehringer Ingelheim: Selected Key Developments, 2019-October 2022
Table 45: Eli Lilly and Co.: Products Portfolio for Type 2 Diabetes Treatment
Table 46: Eli Lilly and Co.: Selected Key Developments, 2020-November 2022
Table 47: Janssen Pharmaceuticals: Products Portfolio for Type 2 Diabetes Treatment
Table 48: Merck & Co. Inc.: Products Portfolio for Type 2 Diabetes Treatment
Table 49: Merck & Co. Inc.: Selected Key Developments, 2020-October 2022
Table 50: Novartis: Products Portfolio for Type 2 Diabetes Treatment
Table 51: Novo Nordisk: Products Portfolio for Type 2 Diabetes Treatment
Table 52: Novo Nordisk: Selected Key Developments, 2019-October 2022
Table 53: Sanofi: Products Portfolio for Type 2 Diabetes Treatment
Table 54: Sanofi: Selected Key Developments, 2020-November 2022
List of Figures
Summary Figure: Global Market Share of Type 2 Diabetes Treatment, by Region, 2021
Figure 1: Type 2 Diabetes Facts
Figure 2: Global Diabetes Incidence
Figure 3: Risk of Developing Diabetes-Related Comorbidities
Figure 4: Global Market Shares of Type 2 Diabetes Treatment, by Route of Administration, 2021
Figure 5: Global Market Shares of Injectable Therapies for Type 2 Diabetes, by Type, 2021
Figure 6: Global Market Shares of Oral Medications for Type 2 Diabetes, by Drug Class, 2021
Figure 7: Global Market Shares of Type 2 Diabetes Treatment, by Therapy Type, 2021
Figure 8: Global Market Shares of Insulin for Type 2 Diabetes Treatment, by Insulin Type, 2021
Figure 9: Global Market Shares of Non-Insulin Therapies for Type 2 Diabetes, by Drug Type, 2021
Figure 10: Global Type 2 Diabetes Treatment Market, by Region
Figure 11: Global Market Share of Type 2 Diabetes Treatment, by Region, 2021
Figure 12: Global Market Shares of Type 2 Diabetes Treatment, by Region, 2027
Figure 13: Global Market Shares of Type 2 Diabetes Therapies Manufacturers, 2021
Figure 14: Global Evolution of the Top-Selling Insulin Brands, 2016-2021
Figure 15: Global Evolution of the Top-Selling Non-Insulin Diabetes Drug Brands, 2016-2021
